Martha Q Lacy

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint New immunomodulatory drugs in myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 6:120-5. 2011
  2. doi request reprint Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 52:560-6. 2011
  3. pmc Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:799-802. 2009
  4. pmc Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
    Martha Q Lacy
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 118:2970-5. 2011
  5. ncbi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
  6. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
  7. ncbi request reprint Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation
    Martha Q Lacy
    Division of Hematology and Internal Medicine, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Arch Dermatol 141:1277-82. 2005
  8. pmc Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States
    Leuk Res 33:1485-9. 2009
  9. pmc Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
    M Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1934-9. 2010
  10. ncbi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008

Detail Information

Publications113 found, 100 shown here

  1. doi request reprint New immunomodulatory drugs in myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 6:120-5. 2011
    ..It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM...
  2. doi request reprint Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 52:560-6. 2011
    ..Pomalidomide is currently not FDA-approved. Herein, we summarize what is currently known about the biologic and therapeutic effects of pomalidomide...
  3. pmc Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:799-802. 2009
    ..This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma...
  4. pmc Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
    Martha Q Lacy
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 118:2970-5. 2011
    ..Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896...
  5. ncbi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  6. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  7. ncbi request reprint Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation
    Martha Q Lacy
    Division of Hematology and Internal Medicine, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Arch Dermatol 141:1277-82. 2005
    ..Herein we describe a novel therapeutic approach. Because autologous hematopoietic stem cell transplantation is effective in other plasma cell proliferative disorders, it may be effective in this setting...
  8. pmc Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States
    Leuk Res 33:1485-9. 2009
    ..3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed...
  9. pmc Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
    M Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1934-9. 2010
    ..The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma...
  10. ncbi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008
    ..Historically, patients with AL amyloidosis and overt congestive heart failure have had an ominous prognosis with median survival of approximately 6 months...
  11. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  12. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  13. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  14. ncbi request reprint Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma
    David Dingli
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 6:384-8. 2006
    ..The impact of cyclophosphamide on CR rates and TTP was evaluated...
  15. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  16. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  17. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  18. pmc High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
    Sumit Madan
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Blood 119:1117-22. 2012
    ..01). In multivariate analysis of baseline factors, only reduced-dose melphalan predicted shorter OS. HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ response is associated with improved survival...
  19. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  20. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  21. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  22. ncbi request reprint Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
    ..To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)...
  23. ncbi request reprint Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, Minnesota, USA
    Clin J Am Soc Nephrol 2:440-4. 2007
    ..Achievement of renal response was associated with improved survival. These results suggest that early intervention with aggressive therapy is not only justified but recommended to achieve optimal response...
  24. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  25. ncbi request reprint Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 89:302-5. 2014
    ..05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control...
  26. ncbi request reprint Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis
    Taxiarchis V Kourelis
    All authors Mayo Clinic, Rochester, MN
    J Clin Oncol 31:4319-24. 2013
    ..The aim of this study was to examine the spectrum of immunoglobulin AL amyloidosis with and without MM, with a goal of defining the optimal bone marrow plasma cell (BMPC) number to qualify as AL amyloidosis with MM...
  27. ncbi request reprint Trends and outcomes of modern staging of solitary plasmacytoma of bone
    Rahma Warsame
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:647-51. 2012
    ..The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up...
  28. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  29. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  30. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  31. doi request reprint Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 115:2348-53; quiz 2560. 2010
    ..5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy...
  32. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  33. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  34. doi request reprint Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:205-11. 2008
    ..Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma...
  35. ncbi request reprint Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis
    Robert J Hoyer
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 82:409-13. 2007
    ..Additional studies are needed to further define the role of bevacizumab in the management of this group of patients...
  36. doi request reprint Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 23:2052-7. 2008
    ..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD...
  37. doi request reprint Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 51:2181-7. 2010
    ..001). The only predictor of survival was cardiac stage (p  < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival...
  38. ncbi request reprint Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
    Shaji K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:614-7. 2008
    ..The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age...
  39. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  40. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  41. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  42. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  43. pmc Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases
    Nelson Leung
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Clin J Am Soc Nephrol 7:1964-8. 2012
    ....
  44. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
    ..The trial was registered at www.clinicaltrials.gov (NCT00564889)...
  45. pmc Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:232-8. 2010
    ..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)...
  46. pmc Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma
    Shirshendu Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 148:853-8. 2010
    ..Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome...
  47. pmc A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 85:409-13. 2010
    ..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting...
  48. ncbi request reprint In vivo and in silico studies on single versus multiple transplants for multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:734-9. 2007
    ..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results...
  49. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  50. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
    ..Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL...
  51. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  52. pmc Outcomes of patients with POEMS syndrome treated initially with radiation
    Michael S Humeniuk
    Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 122:68-73. 2013
    ..The presence of 3 lesions compared with 1 or 2 did not increase risk for treatment failure. Among selected patients with POEMS syndrome, radiation produces durable, meaningful responses. ..
  53. pmc Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, NY, USA
    Blood 119:5397-404. 2012
    ..We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896...
  54. pmc Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 30:989-95. 2012
    ..However, long-term outcome is dependent on the underlying plasma cell clone, and incorporation of clonal characteristics may allow for better risk stratification...
  55. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  56. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  57. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  58. doi request reprint Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years
    Pankaj Malhotra
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1724-30. 2008
    ..All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur...
  59. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  60. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
    ..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma...
  61. ncbi request reprint Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Amyloid 10:257-61. 2003
    ..Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide...
  62. ncbi request reprint A phase II trial of imatinib in patients with refractory/relapsed myeloma
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 47:39-42. 2006
    ..Patients ended treatment due to progressive disease (18 patients), death (3) and other (2). The data suggest that imatinib is not an active agent in patients with relapsed or refractory multiple myeloma...
  63. doi request reprint Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization
    Ivana N M Micallef
    Division of Hematology Blood and Marrow Transplantation, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Biol Blood Marrow Transplant 19:87-93. 2013
    ....
  64. pmc Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  65. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  66. ncbi request reprint Serum M-spike and transplant outcome in patients with multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:1035-40. 2007
    ..The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease...
  67. pmc Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 118:1585-92. 2012
    ..It is not clear whether this paradigm holds true in the context of new therapies, such as immunomodulatory drugs (IMiDs)...
  68. ncbi request reprint The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma
    Yinlee Yoong
    Division of Hematology, Department of Internal Medecine, Mayo Clinic, Rochester, MN 55909, USA
    Leuk Lymphoma 46:1287-94. 2005
    ..0001). Multivariate analysis demonstrated K-ALC recovery post-ASCT to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL...
  69. ncbi request reprint Clinical course of patients with relapsed multiple myeloma
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:867-74. 2004
    ..To study the clinical course of patients with multiple myeloma (MM) that relapses after initial therapy...
  70. ncbi request reprint Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia
    Irene M Ghobrial
    Division of Hematology, Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:158-64. 2006
    ..Beta2-microglobulin > or =4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM...
  71. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  72. doi request reprint The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome
    Anita D'Souza
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 118:4663-5. 2011
    ..Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response...
  73. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  74. ncbi request reprint Relationship between depth of response and outcome in multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 25:4933-7. 2007
    ..We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS...
  75. pmc Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 118:1763-5. 2011
    ..Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide...
  76. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  77. ncbi request reprint Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4319-23. 2002
    ..Thalidomide, an agent with antiangiogenic properties, is effective in relapsed myeloma. We report the results of a study combining thalidomide and dexamethasone as initial therapy for myeloma...
  78. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:343-60. 2006
    ..Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy...
  79. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  80. ncbi request reprint Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement
    Nelson Leung
    Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 5:1660-70. 2005
    ..This experience supports the feasibility of sequential living donor KTx and autologous SCT for carefully selected patients with ESRD due to AL...
  81. pmc Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:2837-40. 2005
    ..The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches...
  82. ncbi request reprint A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL)
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Amyloid 9:24-30. 2002
    ..4'-Iodo-4'-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results...
  83. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  84. ncbi request reprint The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
    Rafael Fonseca
    Mayo Clinic Division of Hematology, The Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Blood 102:2562-7. 2003
    ..The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter...
  85. ncbi request reprint Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma
    Nancy D Borson
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:4629-39. 2002
    ..We hypothesize that premature Blimp-1 expression coupled to altered and deficient Pax5 expression causes some proliferating B cells to prematurely differentiate to plasma cells in MM...
  86. ncbi request reprint Stem cell transplantation for the management of primary systemic amyloidosis
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Med 113:549-55. 2002
    ..To review the characteristics and outcomes of amyloidosis patients treated with high-dose chemotherapy and stem cell reconstitution...
  87. ncbi request reprint Therapy for immunoglobulin light chain amyloidosis: the new and the old
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Blood Rev 18:17-37. 2004
    ..Systemic chemotherapy would not be expected to have any beneficial effect on other forms of amyloid and carries significant risk...
  88. ncbi request reprint Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 92:1415-8. 2007
    ..001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival...
  89. ncbi request reprint Amyloidosis: diagnosis and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Lymphoma Myeloma 6:208-19. 2005
    ..New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide...
  90. ncbi request reprint Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
    Nelson Leung
    Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:270-7. 2005
    ..This study was undertaken to determine the prognostic importance of renal response after high-dose melphalan and stem cell transplantation...
  91. ncbi request reprint Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points
    Angela Dispenzieri
    Mayo Clinic Rochester, MN 55905, USA
    Haematologica 91:390-3. 2006
    ..No anti-myeloma activity was observed in vivo. As administered, flavopiridol has disappointing activity as a single agent in advanced myeloma...
  92. ncbi request reprint Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy
    Deepak Kademani
    Division of Oral Diagnosis and Oral and Maxillofacial Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1100-3. 2006
    ..We describe 2 patients in whom primary surgical salvage was performed successfully for ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with ONJ...
  93. ncbi request reprint Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
    Morie A Gertz
    Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester MN, 55905, USA
    Haematologica 93:1402-6. 2008
    ..The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group...
  94. ncbi request reprint Transplantation for amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 19:136-41. 2007
    ..We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature...
  95. doi request reprint Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study
    Hilmi Ege
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 141:792-8. 2008
    ..This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM...
  96. ncbi request reprint Amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 18:709-27. 2005
    ..This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy...
  97. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  98. ncbi request reprint Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Blood Rev 21:255-65. 2007
    ..Updated diagnostic criteria for these disorders, risk-stratification models to determine prognosis, and the current management of these two entities are discussed in this review...
  99. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  100. ncbi request reprint Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
    ..To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma...
  101. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...